Research Atlas · source screening

Romidepsin

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

272

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Romidepsin"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma.

   Blood Neoplasia · 2026 Nov · PMID 42787871 · DOI 10.1016/j.bneo.2026.100287

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.

   Bioorg Chem · 2026 Aug 15 · PMID 42114191 · DOI 10.1016/j.bioorg.2026.109956

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

   Clin Lymphoma Myeloma Leuk · 2026 Aug · PMID 42414110 · DOI 10.1016/j.clml.2026.06.003

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database.

   Front Oncol · 2026 · PMID 42358560 · DOI 10.3389/fonc.2026.1694602

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

   Blood Adv · 2026 May 26 · PMID 41779512 · DOI 10.1182/bloodadvances.2025019186

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Cross-resistance of Belinostat and Romidepsin in Non-T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP.

   Mol Cancer Ther · 2026 Apr 2 · PMID 41403140 · DOI 10.1158/1535-7163.MCT-25-0941

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.

   J Pharm Health Care Sci · 2026 Mar 27 · PMID 41896949 · DOI 10.1186/s40780-026-00565-3

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy.

   PLoS Biol · 2026 Mar · PMID 41843539 · DOI 10.1371/journal.pbio.3003657

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

   Blood Adv · 2026 Feb 10 · PMID 41609780 · DOI 10.1182/bloodadvances.2025018932

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. A real-world retrospective study of romidepsin: Insights from the Food and Drug Administration Adverse Event Reporting System.

    Medicine (Baltimore) · 2026 Jan 30 · PMID 41630309 · DOI 10.1097/MD.0000000000047449

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma.

    Cancers (Basel) · 2025 Dec 17 · PMID 41463266 · DOI 10.3390/cancers17244018

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Clinical revival of romidepsin with nanoparticles.

    Blood · 2025 Dec 4 · PMID 41343170 · DOI 10.1182/blood.2025031003

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.

    Leuk Lymphoma · 2025 Dec · PMID 40788987 · DOI 10.1080/10428194.2025.2542941

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma.

    Cancer Res Commun · 2025 Oct 1 · PMID 40952917 · DOI 10.1158/2767-9764.CRC-25-0121

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.

    Blood Adv · 2025 Sep 23 · PMID 40179392 · DOI 10.1182/bloodadvances.2024014263

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1.

    Biochem Pharmacol · 2025 Sep · PMID 40419197 · DOI 10.1016/j.bcp.2025.116998

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

    Blood Adv · 2025 Aug 26 · PMID 40526834 · DOI 10.1182/bloodadvances.2025016347

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.

    Nat Commun · 2025 Aug 25 · PMID 40855049 · DOI 10.1038/s41467-025-62934-0

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment.

    Cancers (Basel) · 2025 Jul 17 · PMID 40723261 · DOI 10.3390/cancers17142380

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs).

    Bioorg Chem · 2025 Jun 1 · PMID 40090152 · DOI 10.1016/j.bioorg.2025.108348

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Repurposing Romidepsin for Osteosarcoma: Screening FDA-Approved Oncology Drugs with Three-Dimensional Osteosarcoma Spheroids.

    bioRxiv · 2025 May 24 · PMID 40475499 · DOI 10.1101/2025.05.22.654354

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. NSD2 and miRNAs as Key Regulators of Melanoma Response to Romidepsin and Interferon-α2b Treatment.

    Cancer Med · 2025 May · PMID 40386826 · DOI 10.1002/cam4.70917

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.

    Clin Lymphoma Myeloma Leuk · 2025 May · PMID 39725584 · DOI 10.1016/j.clml.2024.11.015

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor romidepsin using Poly-(D, L-lactide-co-glycolide) nanoparticles as a drug carrier.

    Eur J Pharm Sci · 2025 Apr 1 · PMID 39952370 · DOI 10.1016/j.ejps.2025.107043

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma with Hemophagocytic Syndrome Treated with Romidepsin and Allogeneic Hematopoietic Cell Transplantation.

    Case Rep Oncol · 2025 Jan-Dec · PMID 40129453 · DOI 10.1159/000544782

    Source metadata only · evidence grade unassigned · scientific conclusions pending review